Ranibizumab is an antivascular endothelial growth factor (anti-VEGF) agent that was approved by the Food and Drug Administration in June 2006 for the treatment of CNV due to AMD.2 It is a recombinant humanized immunoglobulin monoclonal antibody fragment (Fab) directed against the receptor-binding domain of all active isoforms of VEGF-A inhibiting cell proliferation (angio-genesis) and reducing vascular leakage.3 It is initially used as a 0.05 mL (0.5 mg) intravitreal (IVT) injection every 4 weeks, with frequency thereafter tailored according to the clinical response. Here, VEGFA is linked to age-related macular degeneration.